EPZ020411 2HCl

CAS No. ——

EPZ020411 2HCl ( —— )

Catalog No. M17704 CAS No. ——

EPZ020411 is an effective and specific small molecule PRMT6 inhibitor (IC50=10 nM).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 189 Get Quote
10MG 301 Get Quote
25MG 627 Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    EPZ020411 2HCl
  • Note
    Research use only, not for human use.
  • Brief Description
    EPZ020411 is an effective and specific small molecule PRMT6 inhibitor (IC50=10 nM).
  • Description
    EPZ020411 is an effective and specific small molecule PRMT6 inhibitor (IC50=10 nM).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Immunology/Inflammation
  • Target
    TLR
  • Recptor
    PRMT6|PRMT1|PRMT8
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    ——
  • Formula Weight
    515.51
  • Molecular Formula
    C25H40Cl2N4O3
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    Cl.Cl.CNCCN(C)Cc1cnnc1c2ccc(cc2)O[C@H]4C[C@H](OCCC3CCOCC3)C4
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Mitchell LH, et al. Aryl Pyrazoles as Potent Inhibitors of Arginine Methyltransferases: Identification of the First PRMT6 ToolCompound. ACS Med Chem Lett. 2015 Apr 6;6(6):655-659.
molnova catalog
related products
  • CPG-52364

    CPG-52364 (CPG52364) is an orally available, small molecule TLR7/8/9 antagonist for the treatment of systemic lupus erythematosus and other autoimmune disorders.

  • Procyanidin B1

    Procyanidin B1, isolated from commonly eaten fruits, binds to the TLR4/MD-2 complex and has anti-inflammatory activity.Procyanidin B1 (100 μg/mL) inhibits LPS-induced TNF-α production, and expression of MD-2, TRAF6, NF-κB mRNA, phosphorylated p38 MAPK and NF-κB protein in THP1 cells.

  • ABR-238901

    ABR-238901 is an oral, active S100A8/A9 blocker that inhibits the interaction of S100A8/A9 with its receptors RAGE(receptor for advanced glycation end products) and TLR4 (toll-like receptor 4). ABR-238901 has potential as a compound for the treatment of myocardial infarction (MI).